Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Preferred Stock
Convertible Preferred Stock
Preferred Stock
Series B preferred stock
Common Shares
Series B preferred stock
Common Shares
Convertible Promissory Note
Common Shares
Additional Paid-in Capital
ASC842 adoption adjustment
Additional Paid-in Capital
Series B preferred stock
Additional Paid-in Capital
Convertible Promissory Note
Additional Paid-in Capital
Accumulated Deficit
Series B preferred stock
Convertible Promissory Note
Total
Balance at Dec. 31, 2022         $ 1,000       $ 226,324,000 $ (228,321,000)     $ (1,996,000)
Balance (in shares) at Dec. 31, 2022         4,750                
Stock-based compensation                 499,000       499,000
Restricted stock awards cancelled (in shares)         0                
Issuance of common stock in connection with convertible securities               $ 708,000       $ 708,000  
Issuance of common stock in connection with convertible securities (In shares)       450                  
Issuance of common stock in connection with warrant exercise                 8,202,000       $ 8,202,000
Issuance of common stock in connection with warrant exercise (in shares)         5,723               5,705
Issuance of common stock, pre-funded units and warrants, net of offering costs                 1,271,000       $ 1,271,000
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)         9,470                
Net loss                   (921,000)     (921,000)
Balance at Mar. 31, 2023         $ 1,000       237,004,000 (229,242,000)     7,763,000
Balance (in shares) at Mar. 31, 2023         20,393                
Balance at Dec. 31, 2022         $ 1,000       226,324,000 (228,321,000)     (1,996,000)
Balance (in shares) at Dec. 31, 2022         4,750                
Net loss                         (6,247,000)
Balance at Jun. 30, 2023         $ 1,000       240,427,000 (234,568,000)     5,861,000
Balance (in shares) at Jun. 30, 2023         35,341                
Balance at Dec. 31, 2022         $ 1,000       226,324,000 (228,321,000)     (1,996,000)
Balance (in shares) at Dec. 31, 2022         4,750                
Balance at Dec. 31, 2023 $ 247,000       $ 1,000       241,884,000 (247,042,000)     (5,157,000) [1]
Balance (in shares) at Dec. 31, 2023 38,335       222,380                
Balance at Mar. 31, 2023         $ 1,000       237,004,000 (229,242,000)     7,763,000
Balance (in shares) at Mar. 31, 2023         20,393                
Stock-based compensation                 481,000       481,000
Restricted stock awards cancelled (in shares)         (1)                
Release of vested restricted common stock (in shares)         1                
Issuance of common stock in connection with warrant exercise                 1,894,000       $ 1,895,000
Issuance of common stock in connection with warrant exercise (in shares)         9,908               12,856
Issuance of common stock, pre-funded units and warrants, net of offering costs                 1,048,000       $ 1,048,000
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)         5,040                
Net loss                   (5,326,000)     (5,326,000)
Balance at Jun. 30, 2023         $ 1,000       240,427,000 (234,568,000)     5,861,000
Balance (in shares) at Jun. 30, 2023         35,341                
Balance at Dec. 31, 2023 $ 247,000       $ 1,000       241,884,000 (247,042,000)     (5,157,000) [1]
Balance (in shares) at Dec. 31, 2023 38,335       222,380                
Stock-based compensation                 380,000       380,000
Stock-based compensation (in shares)         4                
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts   $ 386,000                      
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts (in shares) 29,322                        
Issuance of common stock in connection with conversion of Series B preferred stock   (325,000)                      
Issuance of common stock in connection with conversion of Series B preferred stock (in shares) (5,000)                        
Issuance of common stock in connection with convertible securities             $ 325,000       $ 325,000    
Issuance of common stock in connection with convertible securities (In shares)     8,038                    
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock   5,842,000         (5,842,000)       (5,842,000)    
Repurchase of Series B preferred stock and Series B preferred stock warrants   $ (6,266,000)         $ 824,000       $ 824,000    
Repurchase of Series B preferred stock and Series B preferred stock warrants (in shares) (62,657)                        
Issuance of common stock and warrants, net of offering costs                 4,210,000       4,210,000
Issuance of common stock and warrants, net of offering costs (in shares)         1,442,518                
Issuance of common stock in connection with reverse split rounding-up for fractional shares, shares         84,255                
Net loss                   2,707,000     2,707,000
Balance (Accounting Standards Update 2020-06) at Mar. 31, 2024 $ 116,000               (116,000)       (116,000)
Balance at Mar. 31, 2024         $ 1,000       241,665,000 (244,335,000)     (2,669,000)
Balance (in shares) at Mar. 31, 2024         1,757,195                
Balance at Dec. 31, 2023 $ 247,000       $ 1,000       241,884,000 (247,042,000)     (5,157,000) [1]
Balance (in shares) at Dec. 31, 2023 38,335       222,380                
Net loss                         (39,958,000)
Balance (Accounting Standards Update 2020-06) at Jun. 30, 2024           $ 116,000              
Balance at Jun. 30, 2024         $ 1,000       293,429,000 (287,000,000)     6,430,000
Balance (in shares) at Jun. 30, 2024         4,921,434                
Balance (Accounting Standards Update 2020-06) at Mar. 31, 2024 $ 116,000               (116,000)       (116,000)
Balance at Mar. 31, 2024         $ 1,000       241,665,000 (244,335,000)     (2,669,000)
Balance (in shares) at Mar. 31, 2024         1,757,195                
Stock-based compensation                 241,000       241,000
Stock-based compensation (in shares)         255,915                
Restricted stock awards cancelled (in shares)         (82)                
Release of vested restricted common stock (in shares)         1                
Conversion of liability warrants to equity warrants                 41,851,000       41,851,000
Issuance of common stock in connection with warrant exercise                 556,000       $ 556,000
Issuance of common stock in connection with warrant exercise (in shares)         441,822               3,211
Issuance of common stock, pre-funded units and warrants, net of offering costs                 8,756,000       $ 8,756,000
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)         2,466,583                
Issuance of common stock to vendors                 360,000       360,000
Net loss                   (42,665,000)     (42,665,000)
Balance (Accounting Standards Update 2020-06) at Jun. 30, 2024           $ 116,000              
Balance at Jun. 30, 2024         $ 1,000       $ 293,429,000 $ (287,000,000)     $ 6,430,000
Balance (in shares) at Jun. 30, 2024         4,921,434                
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.